Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Narainrit Karuna has a total of 70 co-authors. Here are the top co-authors by number of shared publications:

  • Chris J. Watson

    Wellcome-Wolfson Institute for Experimental Medicine, Queen’s University, Belfast, Northern Ireland

    4 shared publications
  • Kevin Edgar

    Wellcome-Wolfson Institute for Experimental Medicine, Queen’s University Belfast, Belfast, UK

    3 shared publications
  • Chris Watson

    Queens University Belfast (WELLCOME-WOLFSON INSTITUTE FOR EXPERIMENTAL MEDICINE), Queens University - Welcome Wolfson Inst, Lisburn Road BT9 7BL Belfast,UK, Belfast, ANT BT9 7BL, UK

    2 shared publications
  • Chuda Chittasupho

    Faculty of Pharmacy, Chiang Mai University, Chiang Mai 50200, Thailand

    2 shared publications
  • Karla M O’nEill

    Queen’s University Belfast

    2 shared publications
  • Ken McDonald

    UCD Conway Institute and Research and Innovation Programme for Chronic Disease, School of Medicine, University College Dublin, Dublin, Ireland

    2 shared publications

Latest Publications

  • Open Access

    Proteomic biomarkers differentiate bacterial infections in febrile infants: A multicentre prospective study

    by Clare Mills, Holly Drummond, Narainrit Karuna, Hannah Mitchell, Lisa McFetridge, Oenone Rodgers, Etimbuk Umana, Helen E. Groves, Thomas Waterfield

  • Open Access

    A Nanoparticle-Based Strategy to Stabilize 5-Azacytidine and Preserve DNA Demethylation Activity in Human Cardiac Fibroblasts

    by Kantaporn Kheawfu, Chuda Chittasupho, Sudarshan Singh, Siriporn Okonogi, Narainrit Karuna

    Background: 5-Azacytidine (5-Aza) is a clinically important DNMT inhibitor with the potential to modulate cardiac remodeling by epigenetically reprogramming human cardiac fibroblasts (HCFs). However, its clinical utility is limited by rapid hydrolytic degradation. Nanoparticle (NP) encapsulation offers a strategy to mitigate this instability. This study evaluated the physical and chemical stability of free 5-Aza and 5-Aza-loaded lipid nanoparticles (5-Aza-NP) under different storage temperatures and examined their effects on DNA methylation-related gene expression in HCFs. Methods: Hyaluronic acid-stabilized lipid NPs were prepared using a solvent displacement method. Particle size, polydispersity index (PDI), and zeta potential were monitored over four days at −20 °C, 4 °C, and 30 °C. Chemical stability was assessed using HPLC and first-order kinetic modeling. Functional activity was evaluated by treating HCFs with free 5-Aza or 5-Aza-NP stored for 96 h and measuring DNMT1, DNMT3A, and DNMT3B expression by RT-qPCR. Results: 5-Aza-NP remained physically stable at 4 °C, while −20 °C induced aggregation and 30 °C caused thermal variability. Free 5-Aza degraded rapidly at 30 °C (6.56% remaining at 72 h), whereas 5-Aza-NP preserved 11.54%. Kinetic modeling confirmed first-order degradation, with consistently longer half-lives for the NP formulation. Functionally, 5-Aza–NP preserved its ability to suppress DNMT1 expression following 96 h of storage at 4 °C, whereas free 5-Aza showed reduced activity. In contrast, DNMT3A and DNMT3B levels remained low and unchanged across all treatments. Conclusions: NP encapsulation enhances the physicochemical stability of 5-Aza and preserves its DNMT1-inhibitory activity, while DNMT3A/B remain unaffected. These findings support NP-based delivery as a promising strategy to stabilize labile epigenetic drugs such as 5-Aza.


  • Open Access

    Established and Emerging Roles of Epigenetic Regulation in Diabetic Cardiomyopathy

    by Adam Russell‐Hallinan, Narainrit Karuna, Frank Lezoualc'H, Giuseppe Matullo, Hana Baker, Monique Bernard, Yvan Devaux, Lina Badimon, Gemma Vilahur, Jennifer Rieusset, et al.

    An increasing number of individuals are at high risk of type 2 diabetes (T2DM) and its cardiovascular (CV) complications, which challenges healthcare systems with an increased risk of developing CV diseases. Patients with T2DM exhibit a unique cardiac phenotype termed diabetic cardiomyopathy (DCM). DCM usually involves complex and multifactorial pathogenic drivers, including myocardial inflammation, fibrosis, hypertrophy, and early diastolic dysfunction, which potentially evolve into systolic dysfunction and heart failure. There is a lack of effective treatments for DCM on the basis of the complexity of the disease per se and poor understanding of the mechanisms behind disease development and progression. Despite the considerable research attention on the onset of DCM development and progression, understanding of the full spectrum of pathogenic mechanisms has not yet been fully deciphered. Epigenetic alterations, including DNA methylation, histone modifications, bromodomain extra‐terminal (BET)‐containing reader proteins, and RNA‐based mechanisms (e.g., miRs, lncRNAs, circRNA), are significantly associated with the initiation and evolution of DCM, particularly in the early stage. In this review, we provide insights into the evidence of epigenetic alterations related to DCM development and progression characteristics. Furthermore, the uniqueness of epigenetic changes in DCM in specific cell types within diabetic hearts is discussed. We also review epigenetic cooperation in the context of DCM development and epigenetic biomarkers related to DCM progression. With recent advancements in technology, epitranscriptomics‐related to DCM has been uniquely discussed. Finally, this review may provide new avenues for potential implications for future research and the discovery of novel treatment targets for preventing the onset and progression of DCM.


  • Open Access

    Proteomic-based biomarker discovery reveals panels of diagnostic biomarkers for early identification of heart failure subtypes

    by Narainrit Karuna, Claire Tonry, Mark Ledwidge, Nadezhda Glezeva, Joe Gallagher, Ken McDonald, Chris J. Watson

    Background: Limited access to echocardiography can delay the diagnosis of suspected heart failure (HF), which in turn postpones the initiation of optimal guideline-directed medical therapy. Although natriuretic peptides like B-type natriuretic peptide (BNP) are valuable biomarkers for diagnosing and managing HF, the utility of combining BNP with other blood-based biomarkers to predict subtypes of new-onset HF remains underexplored. Objectives: This study sought to investigate and evaluate the diagnostic significance of adding blood-based biomarkers to BNP for identifying heart failure with preserved ejection fraction (HFpEF) or reduced ejection fraction (HFrEF), with the goal of enhancing diagnostic assays beyond BNP measurements. Methods: We identified candidate blood protein biomarkers using untargeted proteomics workflows from a cohort of individuals recruited to the STOP-HF trial who were at risk of HF and subsequently developed either HFpEF or HFrEF over time (“HF progressors”; n = 40). Candidate biomarkers were verified in an independent cohort (n = 52) from a community-based rapid access HF diagnostic clinic. The biological processes associated with these proteins were assessed, and the diagnostic values of biomarker panels were evaluated using a machine learning approach. Results: Within HF progressors, we identified 3 proteins associated with HFpEF development: vascular cell adhesion protein 1 (VCAM1), insulin-like growth factor 2 (IGF2), and inter-alpha-trypsin inhibitor heavy chain 3 (ITIH3). Additionally, 4 proteins were linked to HFrEF development: C-reactive protein (CRP), interleukin-6 receptor subunit beta (IL6RB), phosphatidylinositol-glycan-specific phospholipase D (PHLD), and noelin (NOE1). These findings were verified in an independent cohort to distinguish HF subtypes from controls. Moreover, a random forest algorithm demonstrated that combining these candidate biomarkers with BNP measurement significantly improved the prediction of HF subtypes. Conclusions: We identified candidate proteins linked to HFpEF and HFrEF in a longitudinal HF progressor cohort and validated them in a community-based cohort. Adding these proteins to BNP led to a significant improvement in HF subtype prediction. Study results have clinical implications for blood-based screening of HF subtypes using panels of biomarkers, particularly in resource-limited settings.


  • Open Access

    Sacubitril/Valsartan attenuates progression of diabetic cardiomyopathy through immunomodulation properties: an opportunity to prevent progressive disease

    by Narainrit Karuna, Lauren Kerrigan, Kevin Edgar, Mark Ledwidge, Ken McDonald, David J. Grieve, Chris J. Watson

    Background and aims: Diabetic cardiomyopathy (DbCM) is recognised as a key mediator and determinant of heart failure (HF), particularly HF with preserved ejection fraction (HFpEF). Improved understanding of mechanisms underlying transition from early-stage DbCM to HFpEF will inform innovative evidence-based treatment approaches, which are urgently required to alleviate increasing disease burden. This study aimed to determine whether inhibition of neprilysin activity by Sacubitril/Valsartan in both experimental and clinical DbCM attenuates adverse remodelling through promotion of cardioprotective signalling. Methods and results: Sacubitril/Valsartan effectively reduced plasma neprilysin activity in both diabetic patients with pre-clinical HFpEF from the PARABLE trial (baseline (Val n = 25; Sac/Val n = 35) and 3 months after treatment (Val n = 21/25; Sac/Val n = 33/35)) and DbCM (high-fat diet and streptozotocin) mice. Plasma neprilysin activity at baseline was correlated with worsening cardiac performance at 18 months indicated by left atrial stiffness index in patients (n = 44/60), whilst diastolic dysfunction and pathological remodelling in DbCM mice were improved by Sacubitril/Valsartan, but not Valsartan. snRNA-sequencing showed that progressive experimental DbCM is characterised by chronic low-grade inflammation, reflected by increased infiltration of pro-inflammatory monocytes (Ccr2+ Ly6chi) and reduction in MHC-II macrophages, which was prevented by Sacubitril/Valsartan. Informatics analysis implicated IRF7 as a central mediator of Sacubitril/Valsartan-induced immunomodulation in DbCM, whilst treatment of M2-like pro-repair macrophages with the neprilysin inhibitor, LBQ657 and Valsartan suppressed glucose-induced IRF7 expression and paracrine activation of cardiac fibroblast differentiation in vitro. Conclusion: Immune cells are significantly involved in DbCM progression, impacting myocardial homeostasis and HF progression. Neprilysin inhibition by Sacubitril/Valsartan improved adverse cardiac remodelling in experimental DbCM through direct regulation of inflammation, highlighting immunomodulation as a novel mechanism underlying established its cardioprotective actions. Graphical


  • Open Access

    Proteome Alterations in Cardiac Fibroblasts: Insights from Experimental Myocardial Infarction and Clinical Ischaemic Cardiomyopathy

    by Adam Russell-Hallinan, Claire Tonry, Lauren Kerrigan, Kevin Edgar, Patrick Collier, Ken McDonald, Mark Ledwidge, David Grieve, Narainrit Karuna, Chris Watson

    Ischaemic heart disease (IHD) is a chronic condition that can cause pathological cardiac remodelling and heart failure (HF). In this study, we sought to determine how cardiac fibroblasts were altered post-experimental myocardial infarction (MI). Female C57BL6 mice underwent experimental MI by permanent left coronary artery ligation. Cardiac fibroblasts were isolated from extracted heart tissue of experimental MI mice and subsequently treated with the pro-fibrotic cytokine, TGF-β, for 24 h and analysed using high throughput LC-MS/MS analysis. Findings were validated using mass spectrometry data generated from human left ventricular tissue analysis, which were collected from patients with ischaemic cardiomyopathy (ISCM) and age/sex-matched patients without clinical HF (NF). Proteomic analysis revealed significant protein expression changes in mouse cardiac fibroblasts after MI. These changes were most pronounced at 1 month post-MI, compared to earlier time points (3 days and 1 week). TGF-β treatment profoundly affected fibroblast cells extracted from MI mice, indicating a heightened sensitivity to pro-fibrotic factors after myocardial injury. Extracellular matrix (ECM) proteins significantly altered in MI fibroblasts following TGF-β treatment were significantly associated with cardiac remodelling. Notably, Lox was significantly changed in both isolated fibroblasts treated with TGF-β from experiment MI mice and human ISCM. Isolated cardiac fibroblasts from MI mice are more susceptible to developing pathogenic traits following TGF-β treatment than isolated fibroblasts from normal heart tissue. ECM proteins associated with these enhanced fibroblast activities and functions are evident. These altered proteins may play a functional role in MI-associated cardiac dysfunction.


  • Open Access

    Phytochemical Characterization and Anticancer Activity of Clerodendrum chinense Leaf Extract Against Breast and Cervical Cancer Cells

    by Chuda Chittasupho, Weerasak Samee, Supachoke Mangmool, Narainrit Karuna, Songyot Anuchapreeda, Siriporn Okonogi, Sirivan Athikomkulchai

    Cancer remains a significant global health challenge, necessitating novel therapeutic interventions. Clerodendrum chinense leaf extract (CCL) has gained interest for its potential anticancer properties due to its bioactive composition. This study aims to evaluate the cytotoxic effects of CCL against MCF-7 breast cancer and HeLa cervical cancer cells and elucidate its mechanisms of action. High-performance liquid chromatography identified verbascoside, isoverbascoside, and hispidulin as the major bioactive compounds. CCL exhibited time- and dose-dependent cytotoxicity, with MCF-7 cells showing greater sensitivity (IC50 = 126.8 µg/mL, 72 h) than HeLa cells (216.1 µg/mL, 72 h). Flow cytometry confirmed apoptotic induction, with late apoptosis increasing at moderate concentrations (16.03–23.55%) and necrosis prevailing at higher doses (50.80–63.68%). Reactive oxygen species generation was significantly elevated in MCF-7 (70.2%) and HeLa (60.4%) cells at 250 µg/mL. CCL effectively suppressed colony formation and cell migration in a dose-dependent manner. Molecular docking studies demonstrated that apoptosis induction of CCL bioactive compounds may mediate through the pro-apoptotic BCL2 associated X, apoptosis regulator (BAX) regulator. These findings highlight the potential of CCL as a natural anticancer agent with multiple mechanisms, including reactive oxygen species (ROS)-induced apoptosis, BAX activation, and inhibition of proliferation and metastasis.


  • Open Access

    Signature of diabetic cardiomyopathy progression using high-fat diet and streptozotocin mouse model: from subclinical to clinical with three-hit mouse model

    by N Karuna, L Kerrigan, K Edgar, C Tonry, D Grieve, C Watson

    Background: Diabetic cardiomyopathy (DbCM) is a pre-heart failure (pre-HF) condition that usually exhibits early diastolic dysfunction and evolving systolic dysfunction, along with left ventricular (LV) remodelling. Although DbCM shows distinct pathophysiology, the transition from the subclinical to the symptomatic stage is not straightforward and usually involves multifaceted processes which are not fully understood. Purpose: To define the signature of DbCM progression in a novel mouse model using longitudinal echocardiography and multi-omics approaches. Methods: Male mice (C57BL/6) were fed with high-fat diet (HFD) or control diet (CD) for 24 weeks, with single dose of streptozotocin (STZ) or vehicle injection at 8 weeks (n=10 each). Serial functional and metabolic parameters were measured prior to endpoint single nuclei RNA sequencing (snRNA-seq) and mass spectrometry-based proteomics analysis with comparison to cardiac remodelling to define detailed mechanisms underlying DbCM progression. Results: HFD/STZ mice developed type 2 diabetes mellitus (T2DM) based on higher fasting blood glucose and HbA1C levels, insulin resistance and decreased beta-cell function (HOMA-IR and HOMA-beta, respectively) compared to controls. Progressive diastolic dysfunction was evident in HFD/STZ mice compared to CD mice based on enlarged LVPW;d from 12 weeks (P<0.05), reduced MV E/A ratio (P<0.01) and IVRT (P<0.05) from 16 weeks, and increased cardiac filling pressure (Left atrial (LA) area and LA volume) at 24 weeks, with preserved systolic function. This was paralleled by elevated collagen deposition (Picrosirius red), myocyte cross-sectional area and Col1a1 expression in HFD/STZ versus CD mice (all P<0.05). snRNA-seq analysis indicated preferential monocyte migration into diabetic hearts (P<0.01) whilst inflammatory pathways were activated across all cardiac cell types. Proteomics analysis revealed elevated expression of the established inflammation marker, plasma C-reactive protein (CRP), in HFD/STZ versus CD mice (P<0.05), which was correlated with worsening diastolic function (MV E/A ratio: r=-0.839, P<0.01) and LV hypertrophy (LVPW;d: r=0.861, P<0.01). Conclusion: Our HFD/STZ mouse model offers a ‘three-hit’ approach which effectively captures key stages of clinical DbCM progression: 1) T2DM with insulin resistance, 2) progressive diastolic dysfunction with elevated chronic filling pressure and cardiac remodelling, and 3) systemic inflammation. This improved HFD/STZ mouse model is therefore appropriate to support a detailed study of mechanisms underlying DbCM progression and subsequent translation.

  • 2147: Entresto as a novel radioprotectant in a partial heart irradiation mouse model

    by Gerard M. Walls, Mihaela Ghita, Narainrit Karuna, Kevin S. Edgar, Kathryn H. Brown, Rachel Queen, Chris J. Watson, Karl T. Butterworth

  • Open Access

    BS08 ISG15 signalling promotes coronary microvascular endothelial dysfunction in experimental diabetes

    by Mohammed Alsaggaf, Lauren Kerrigan, Kevin Edgar, Narainrit Karuna, Karla M O’nEill, Shun Hay Pun, Oisin Cappa, Chris Watson

    Objective Diabetic cardiomyopathy (DCM) is a common complication of type 2 diabetes, which is characterised by dysfunction of the coronary microvascular endothelium as an important determinant of adverse cardiac remodeling. Whilst multiple signaling pathways are linked with DCM, specific mediators remain poorly understood. This study focused on interferon-stimulated gene 15 (ISG15) as a novel driver of endothelial dysfunction in experimental DCM and potential therapeutic target. Methods and Results Ingenuity Pathway Analysis (IPA) was performed on data obtained from both bulk and single nuclei RNAseq analyses of mouse DCM tissue using R and Partek. Data sets met the criteria of an adjusted p-value of 0.05 and a log2 fold change ranging from -1.5 to 1.5, focusing on differentially expressed genes with endothelial cell enrichment. Interferon signalling and activation of interferon-related factors were identified as the most significantly altered canonical pathways linked with endothelial dysfunction, with expression of several component genes found to be significantly upregulated within the dataset, including ISG15 which was validated by real time RT-PCR analysis of DCM mouse tissue. Parallel in vitro studies established treatment of human coronary microvascular endothelial cells (HCMECs) with 25 mmol/L D-glucose for 14 days (versus L-glucose osmotic control) as a reliable model of experimental diabetes, characterised by barrier dysfunction (increased FITC-Dextran transfer, reduced expression of e.g. ZO-1, claudin-5, β-catenin) and significantly increased ISG15 expression. ISG15 siRNA knockdown restored high glucose-induced HCMEC barrier dysfunction and expression of the key adherens junction protein, β-catenin, but had no impact on expression of tight junction proteins, ZO-1 and claudin-5. Conclusion Taken together, these data highlight ISG15 is an important driver of coronary microvascular endothelial dysfunction in experimental diabetes which may represent a potential therapeutic target to reduce progression of adverse cardiovascular remodelling. Conflict of Interest none